In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated. Among different available publications, three of them were integrated into the final analysis leading the authors to interesting conclusions: “In the era of antibiotic resistance, an antibiotic-sparing approach presents an interesting alternative treatment of uncomplicated cystitis in women…“ and “A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance”, thus reinforcing the usefulness of Utipro® Plus/Utipro® Plus AF in acute and recurrent uncomplicated UTIs.
After the publication of the first paper in which the significant antioxidant activity of Olea europaea leaf extract (OELE) was observed and assessed, we are happy to announce the second publication related to the hydrogel (EHO-85) based on OELE, indicated for the healing of wounds of full and partial thickness.
The first clinical evidence related to an hydrogel based on Olea europaea leaf extract (EHO‐85) indicated for the healing of wounds of full and partial thickness has been published in the Journal of Clinical Medicine.